Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

Market Trends, Business Strategies, Competitive Intelligence, Clinical Trials, and Patent Trends Driving Growth from 2024 to 2029"Boston, July 10, 2025 (GLOBE NEWSWIRE) -- According to the latest ...

Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

US FDA eliminates REMS for autologous chimeric antigen receptor CAR T cell immunotherapies: Maryland Monday, June 30, 2025, 13:00 Hrs [IST] The US Food and Drug Administration (FD ...

With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...